Spironolactone
Spironolactone, sold as Aldactone, is an aldosterone antagonist, a medicine taken by mouth that blocks the hormone aldosterone. The US label read, for Aldactone tablets, lists four uses: heart failure with reduced ejection fraction in people with the more severe symptom classes (NYHA class III to IV), to increase survival, manage swelling and reduce hospital stays for heart failure; add-on treatment of high blood pressure; swelling in adults with cirrhosis of the liver or in the nephrotic syndrome when the measures the label names first have not worked well enough; and primary hyperaldosteronism.
Also called Aldactone
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 9997; UNII 27O7W4T232. MeSH descriptor D013148 is Spironolactone. Class: Aldosterone Antagonist (FDA established pharmacologic class, RxClass). The label read is the Pfizer Laboratories Div Pfizer Inc label for Aldactone tablets, application NDA012151, effective 2025-11-28 in openFDA. The plan row pointed at a spironolactone and hydrochlorothiazide combination label; the single-ingredient brand label replaces it. The combination product (Aldactazide, NDA012616) and generic labels were not read. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says spironolactone and its active metabolites are specific pharmacologic antagonists of aldosterone.
Claims and evidence
Context Patients with NYHA class III to IV heart failure (reduced ejection fraction), hypertension, edema or primary hyperaldosteronism, as described in the US label of Aldactone tablets
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label: people with NYHA class III to IV heart failure and reduced ejection fraction, people with hypertension, adults with edema from cirrhosis of the liver or the nephrotic syndrome, and people with primary hyperaldosteronism. The passages read do not state an age range for each use.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated for each use in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 4 inclusion criteria; exclusion criteria not stated
- Included
- Patients with NYHA Class III to IV heart failure and reduced ejection fraction
- Patients with hypertension who are not adequately controlled on other agents
- Patients with edema in cirrhosis of the liver or the nephrotic syndrome
- Patients with primary hyperaldosteronism
- Excluded
- None stated
The US label of Aldactone (spironolactone tablets, Pfizer Laboratories Div Pfizer Inc, application NDA012151; the version dated 2025-11-28 in openFDA) describes spironolactone as an aldosterone antagonist. It lists the treatment of NYHA class III to IV heart failure with reduced ejection fraction to increase survival, manage edema and reduce the need for hospitalization for heart failure; add-on treatment of hypertension; the management of edema in cirrhosis of the liver and in the nephrotic syndrome in the settings the label names; and treatment of primary hyperaldosteronism, as short-term preoperative treatment and as long-term maintenance therapy in the settings the label names.
Applies to Recipient not specified Patients with NYHA class III to IV heart failure (reduced ejection fraction), hypertension, edema or primary hyperaldosteronism, as described in the US label of Aldactone tablets
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label says the heart failure use is usually together with other heart failure therapies; that is not an atlas recommendation. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (6)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2025-11-28
- Source state
- Current
- Version fingerprint
7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.1 Heart Failure
- How it applies
- Label passage quoted in the research quote table (LB-05, LB-10).
- Retrieved
- Source effective date
- 2025-11-28
- Source state
- Current
- Version fingerprint
7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.2 Hypertension
- How it applies
- Label passage quoted in the research quote table (LB-06).
- Retrieved
- Source effective date
- 2025-11-28
- Source state
- Current
- Version fingerprint
7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.3 Edema Associated with Hepatic Cirrhosis or Nephrotic Syndrome
- How it applies
- Label passage quoted in the research quote table (LB-07, LB-11).
- Retrieved
- Source effective date
- 2025-11-28
- Source state
- Current
- Version fingerprint
7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.4 Primary Hyperaldosteronism
- How it applies
- Label passage quoted in the research quote table (LB-08, LB-12).
- Retrieved
- Source effective date
- 2025-11-28
- Source state
- Current
- Version fingerprint
7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251128.
- Retrieved
- Source effective date
- 2025-11-28
- Source state
- Current
- Version fingerprint
7a66be80d86367d4142306a143a4c600b7a1fd0b1e32977782824e8cd08cdc91- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists NYHA class III to IV heart failure with reduced ejection fraction as an indication: Heart failure with reduced ejection fraction (HFrEF)
Applies to Recipient not specified Patients with NYHA class III to IV heart failure (reduced ejection fraction), hypertension, edema or primary hyperaldosteronism, as described in the US label of Aldactone tablets
The US label of Aldactone (spironolactone tablets, Pfizer Laboratories Div Pfizer Inc, application NDA012151; the version dated 2025-11-28 in openFDA) describes spironolactone as an aldosterone antagonist. It lists the treatment of NYHA class III to IV heart failure with reduced ejection fraction to increase survival, manage edema and reduce the need for hospitalization for heart failure; add-on treatment of hypertension; the management of edema in cirrhosis of the liver and in the nephrotic syndrome in the settings the label names; and treatment of primary hyperaldosteronism, as short-term preoperative treatment and as long-term maintenance therapy in the settings the label names.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label says the heart failure use is usually together with other heart failure therapies; that is not an atlas recommendation. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists add-on treatment of hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified Patients with NYHA class III to IV heart failure (reduced ejection fraction), hypertension, edema or primary hyperaldosteronism, as described in the US label of Aldactone tablets
The US label of Aldactone (spironolactone tablets, Pfizer Laboratories Div Pfizer Inc, application NDA012151; the version dated 2025-11-28 in openFDA) describes spironolactone as an aldosterone antagonist. It lists the treatment of NYHA class III to IV heart failure with reduced ejection fraction to increase survival, manage edema and reduce the need for hospitalization for heart failure; add-on treatment of hypertension; the management of edema in cirrhosis of the liver and in the nephrotic syndrome in the settings the label names; and treatment of primary hyperaldosteronism, as short-term preoperative treatment and as long-term maintenance therapy in the settings the label names.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label says the heart failure use is usually together with other heart failure therapies; that is not an atlas recommendation. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists primary hyperaldosteronism as an indication: Primary aldosteronism
Applies to Recipient not specified Patients with NYHA class III to IV heart failure (reduced ejection fraction), hypertension, edema or primary hyperaldosteronism, as described in the US label of Aldactone tablets
The US label of Aldactone (spironolactone tablets, Pfizer Laboratories Div Pfizer Inc, application NDA012151; the version dated 2025-11-28 in openFDA) describes spironolactone as an aldosterone antagonist. It lists the treatment of NYHA class III to IV heart failure with reduced ejection fraction to increase survival, manage edema and reduce the need for hospitalization for heart failure; add-on treatment of hypertension; the management of edema in cirrhosis of the liver and in the nephrotic syndrome in the settings the label names; and treatment of primary hyperaldosteronism, as short-term preoperative treatment and as long-term maintenance therapy in the settings the label names.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label says the heart failure use is usually together with other heart failure therapies; that is not an atlas recommendation. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:spironolactone- Content hash
623116861745a51c1146b1091d7a921d11dfd2f1ae34d642fa946fff70c173a3